The agreement provides Novo Nordisk with full access to Emisphere’s Eligen SNAC technology, which will boost Novo Nordisk’s portfolio of oral therapeutics.
Novo Nordisk, a healthcare company based in Denmark, announced on Nov. 6, 2020 that it is acquiring Emisphere Technologies, a US-based drug delivery company, for $1.8 billion.
Under the terms of the acquisition, Novo Nordisk will obtain all outstanding shares of Emisphere for $1.35 billion and all of Emisphere’s Eligen SNAC royalty stream obligations for $450 million, a Novo Nordisk press release said.
The agreement provides Novo Nordisk with full access to Emisphere’s Eligen SNAC technology, used to develop Rybelsus (semaglutide), touted as the first oral biologic, and will give Novo Nordisk the opportunity to expand its oral drug pipeline portfolio, including the ability to develop oral formulations for biologics.
“We intend to apply and further develop the technology and use it on current and future pipeline assets with the aim of making more biologic medicines orally available for patients,” said Mads Krogsgaard Thomsen, executive vice-president and chief scientific officer of Novo Nordisk, in the press release.
Source: Novo Nordisk
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.